BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Orencia (Abatacept) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Orencia (Abatacept)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05428488-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT05428488)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: E
 fficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428488
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05621759-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT05621759)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Cyclophosphamide\, Abata
 cept\, and Tacrolimus for the Prevention of GvHD\nEstimated primary comple
 tion: 30 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abatacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05621759
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03924401-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT03924401)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Acute GVHD Suppression U
 sing Costimulation Blockade to Expand Non-malignant Transplant\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03924401
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388563-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Orencia (Abatacept): Phase 1 readout est. (NCT07388563)
DESCRIPTION:Orencia (Abatacept)\, phase 1.\nStudy: Azacitidine and Abatacep
 t in Relapsed or Refractory T-Cell Lymphoma\nEstimated primary completion:
  31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abata
 cept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07388563
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03929601-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT03929601)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Rituximab-pvvr and Abata
 cept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03929601
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380740-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT04380740)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Extended vs Short-term A
 batacept Dosing for Graft Versus Host Disease Prophylaxis\nEstimated prima
 ry completion: May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/abatacept#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04380740
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366801-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Orencia (Abatacept): Phase 2/3 readout est. (NCT07366801)
DESCRIPTION:Orencia (Abatacept)\, phase 2/3.\nStudy: Co-infusion of Treg-en
 riched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft t
 o Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Ce
 ll Transplantation Among Children With Hematologic Malignancies\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07366801
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05917522-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT05917522)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Assessment of Biomarker-
 Guided CNI Substitution In Kidney Transplantation\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aba
 tacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05917522
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008808-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Orencia (Abatacept): Phase 1 readout est. (NCT06008808)
DESCRIPTION:Orencia (Abatacept)\, phase 1.\nStudy: Ruxolitinib With and Wit
 hout CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease 
 and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripher
 al Blood Hematopoietic Cell Transplantation\nEstimated primary completion:
  8 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 atacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06008808
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289167-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Orencia (Abatacept): Phase 1/2 readout est. (NCT05289167)
DESCRIPTION:Orencia (Abatacept)\, phase 1/2.\nStudy: Post-Transplant Cyclop
 hosphamide\, Bortezomib and Abatacept for the Prevention of Graft-versus-H
 ost-Disease (GvHD)\nEstimated primary completion: November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/abatacept#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05289167
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731504-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Orencia (Abatacept): Phase 1 readout est. (NCT06731504)
DESCRIPTION:Orencia (Abatacept)\, phase 1.\nStudy: HMCT/CT2401: Abatacept G
 VHD Prophylaxis Following Omidubicel HCT\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abatacep
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 731504
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238712-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT07238712)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Optimization of Post-tra
 nsplantation Benadamustine and Cyclophosphamide in Patients With High-risk
  Myeloid Malignancies and a Partially Mismatched Donor\nEstimated primary 
 completion: 10 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07238712
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Immunosuppressant Manage
 ment in Rheumatology Patients Undergoing Elective Total Shoulder Arthropla
 sty\nEstimated primary completion: January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/abatacept#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859424-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT06859424)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: A Platform Protocol to I
 nvestigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Diseas
 e Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatc
 hed Unrelated Donor Peripheral Blood Stem Cell Transplantation\nEstimated 
 primary completion: June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06859424
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04925375-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT04925375)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Abatacept for the Treatm
 ent of Common Variable Immunodeficiency With Interstitial Lung Disease\nEs
 timated primary completion: July 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04925375
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05335928-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20290409
DTEND;VALUE=DATE:20290410
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT05335928)
DESCRIPTION:Orencia (Abatacept)\, phase 3.\nStudy: Abatacept in Immune Chec
 kpoint Inhibitor Myocarditis\nEstimated primary completion: 9 April 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/abatacept#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05335928
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06654882-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT06654882)
DESCRIPTION:Orencia (Abatacept)\, phase 3.\nStudy: Trial of Sequential Medi
 cations AfteR TNFi Failure in Juvenile Idiopathic Arthritis\nEstimated pri
 mary completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06654882
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04474847-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT04474847)
DESCRIPTION:Orencia (Abatacept)\, phase 3.\nStudy: Abatacept for the Treatm
 ent of Giant Cell Arteritis\nEstimated primary completion: December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/abatacept#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04474847
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599176-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Orencia (Abatacept): Phase 1/2 readout est. (NCT07599176)
DESCRIPTION:Orencia (Abatacept)\, phase 1/2.\nStudy: Partial Stem Cell Tran
 splant for Sickle Cell Disease From Matched Donors\nEstimated primary comp
 letion: 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abatacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07599176
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616154-96@assetmemo.bio
DTSTAMP:20261121T003059Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Orencia (Abatacept): Phase 2 readout est. (NCT07616154)
DESCRIPTION:Orencia (Abatacept)\, phase 2.\nStudy: Haploidentical Donor Hem
 atopoietic Cell Transplant for Sickle Cell Disease\nEstimated primary comp
 letion: September 2034. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/abatacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07616154
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
